X0508 4 2023-10-18 0 0001888886 Structure Therapeutics Inc. GPCR 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 1 1 See Remark 1 0 Ordinary Shares 45120 I F-Prime Capital Partners Life Sciences Advisors Fund VI LP Ordinary Shares 530814 I F-Prime Capital Partners Life Sciences Fund VI LP American Depositary Shares Ordinary Shares 4769400 1589800 I Shares held by persons and entities whose shares are subject to reporting by the undersigned American Depositary Shares Ordinary Shares 123 41 I FIMM, LLC American Depositary Shares 2023-10-18 4 S 0 1368 65.64 D Ordinary Shares 4104 4101 I F-Prime Capital Partners Life Sciences Advisors Fund VI LP American Depositary Shares 2023-10-18 4 S 0 16086 65.64 D Ordinary Shares 48258 48255 I F-Prime Capital Partners Life Sciences Fund VI LP Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC. Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2023-10-23